Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Adherium Ltd. ( (AU:ADR) ) has shared an announcement.
Adherium Limited has reported substantial growth in its remote patient monitoring (RPM) subscription revenues, with a projected 103.1% increase quarter-on-quarter for Q2 FY26. The company’s strategic partnerships and clinic activations have driven this growth, positioning RPM as a key revenue channel and enhancing Adherium’s market presence in digital respiratory management.
The most recent analyst rating on (AU:ADR) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Adherium Ltd. stock, see the AU:ADR Stock Forecast page.
More about Adherium Ltd.
Adherium Limited is a global leader in digital respiratory management, known for developing the FDA-cleared Hailie® Smartinhaler® platform. The company focuses on remote patient monitoring (RPM) for respiratory conditions, with a significant presence in the US market.
Technical Sentiment Signal: Sell
Current Market Cap: A$10.05M
See more insights into ADR stock on TipRanks’ Stock Analysis page.